Oarsman Capital’s ClearPoint Neuro CLPT Stock Holding History

Oarsman Capital’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-5,000	Closed	-$76.9K	–	360
2024 Q4	$76.9K	Hold	5,000	–	–	0.01%	374
2024 Q3	$56K	Buy	+5,000	New	+$47.9K	0.01%	429

Other funds holding CLPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CWM

Cahill Wealth Management Portage, Michigan $196M AUM 8.5% 1-Year Est. Return

Oarsman Capital's CLPT Position: Q1 2025 in Review

Oarsman Capital sold out of ClearPoint Neuro (CLPT) in Q1 2025, closing a stake of 5,000 shares — an estimated $76.9K sold.

Oarsman Capital first reported a position in CLPT in Q3 2024 and held it in 2 quarters. The position peaked at $76.9K in Q4 2024. 101 funds tracked by Wall St. Rank hold CLPT as of Q1 2025.

Oarsman Capital reported no remaining ClearPoint Neuro position as of Q1 2025 after selling out during the quarter.
Oarsman Capital sold 5,000 ClearPoint Neuro shares in Q1 2025, an estimated $76.9K.
Oarsman Capital first reported a position in ClearPoint Neuro in Q3 2024 and held it in 2 quarters.
Oarsman Capital's ClearPoint Neuro position peaked at $76.9K in Q4 2024.
101 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q1 2025.

Based on Oarsman Capital's 13F filing for Q1 2025, filed 14 May 2025.